Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Second Edition

Front Cover
Ronald Bukowski, Robert A. Figlin, Robert Motzer
Springer Science & Business Media, Feb 8, 2009 - Medical - 506 pages

In the second edition of their critically acclaimed book, Ronald Bukowski, Robert Motzer, and Robert Figlin have thoroughly updated and expanded their survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma. A panel of internationally renowned contributors explores the latest developments in molecular genetics, focusing on the novel targets that have been discovered in epithelial renal tumors. The discussion includes the specific biology of selected target molecules or receptors and the various agents that inhibit these targets, including full chapters devoted to drugs that selectively inhibit receptor tyrosine kinases, such as sunitinib and axitinib. Further attention is paid to leading-edge strategies that target and inhibit tumor associated angiogenesis and block the vascular endothelial growth factor pathway. Comprehensive and authoritative, Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Second Edition is the definitive text on the rapidly evolving landscape of experimental therapeutics, written and edited by the pioneers of the field.

 

What people are saying - Write a review

We haven't found any reviews in the usual places.

Contents

Chapter 1
1
Chapter 2
13
Chapter 3
34
Chapter 4
49
Chapter 5
79
Chapter 6
99
Chapter 7
119
Chapter 8
150
Chapter 15
267
Chapter 16
286
Chapter 17
305
Chapter 18
321
Chapter 19
335
Chapter 20
347
Chapter 21
367
Chapter 22
404

Chapter 9
167
Chapter 10
188
Chapter 11
195
Chapter 12
210
Chapter 13
231
Chapter 14
248
Chapter 23
425
Chapter 24
449
Chapter 25
472
Index
497
Copyright

Other editions - View all

Common terms and phrases

Bibliographic information